1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21933
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMichalis, L. K.en
dc.contributor.authorKatsouras, C. S.en
dc.contributor.authorPapamichael, N.en
dc.contributor.authorAdamidis, K.en
dc.contributor.authorNaka, K. K.en
dc.contributor.authorGoudevenos, J.en
dc.contributor.authorSideris, D. A.en
dc.date.accessioned2015-11-24T19:19:07Z-
dc.date.available2015-11-24T19:19:07Z-
dc.identifier.issn1097-6744-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21933-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAngina, Unstable/*drug therapy/mortalityen
dc.subjectEnoxaparin/adverse effects/*therapeutic useen
dc.subjectFemaleen
dc.subjectFibrinolytic Agents/*therapeutic useen
dc.subjectHeparin, Low-Molecular-Weight/adverse effects/*therapeutic useen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMyocardial Infarction/*drug therapy/mortalityen
dc.subjectProspective Studiesen
dc.subjectRecurrenceen
dc.titleEnoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trialen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/S0002-8703(03)00179-0-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12891200-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0002870303001790/1-s2.0-S0002870303001790-main.pdf?_tid=33958277b69f6dad81c2acfd0c5ff2f4&acdnat=1337844990_344fe2529e20f171e0edbd81e91ce029-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractBACKGROUND: Low-molecular weight heparins have different pharmacokinetic and pharmacodynamic characteristics and may vary in efficacy. We compared the efficacy of enoxaparin with that of tinzaparin in the management of non-ST-segment elevation acute coronary syndromes (NSTACS). METHODS: A total of 438 patients with NSTACS were randomized to receive subcutaneous treatment with enoxaparin, 100 IU/kg twice daily (equivalent to 1 mg/kg twice daily; n = 220), or tinzaparin, 175 IU/kg once daily, (n = 218) for as long as 7 days. The primary composite end point was recurrent angina, myocardial infarction (or reinfarction), or death at day 7. Secondary end points were the primary end point at day 30 and the occurrence of individual events at days 7 and 30. RESULTS: The incidence of the primary end point was 12.3% in the enoxaparin group and 21.1% in the tinzaparin group (P =.015). At day 7, the rate of recurrent angina was lower with enoxaparin than with tinzaparin (11.8% vs 19.3%). At day 30, the incidences of the composite end point, recurrent angina, and myocardial infarction were also lower with enoxaparin, 17.7% vs 28.0% (P =.012), 17.3% vs 26.1% and 0.5% vs 2.8%, respectively. The rate of revascularization was lower in the enoxaparin group, 8.6% vs 17.9% (P =.010) at day 7 and 16.4% vs 26.1% (P =.019) at day 30. Rates of bleeding complications were similar in the 2 treatment groups. CONCLUSIONS: This study indicates a benefit of enoxaparin (100 IU/kg twice daily) as compared with tinzaparin (175 IU/kg once daily) in the treatment of patients with NSTACS, which is sustained for at least 30 days.en
heal.journalNameAm Heart Jen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Michalis-2003-Enoxaparin versus ti.pdf103.71 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons